Form 4: Centessa CEO Accardi Reports Equity Transactions

Centessa Pharmaceuticals CEO Mario Alberto Accardi reported the acquisition of 68,000 Restricted Share Units and 273,000 share options, alongside a tax-related disposition of 2,915 ordinary shares.

Summary

• Mario Alberto Accardi, Centessa Pharmaceuticals plc's Chief Executive Officer and Director, reported several equity transactions.
• On February 1, 2026, 2,915 ordinary shares were disposed of at a price of $24.57 per share to cover tax withholding obligations related to the vesting of restricted share units.
• Following this disposition, Accardi beneficially owned 175,886 ordinary shares directly.
• On February 2, 2026, Accardi acquired 68,000 Restricted Share Units (RSUs) at a price of $0, issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan.
• These RSUs will vest in four equal annual installments, with the first vesting on February 2, 2027.
• After the RSU acquisition, Accardi's direct beneficial ownership of ordinary shares increased to 243,886.
• Also on February 2, 2026, Accardi acquired 273,000 share options at a price of $0, with an exercise price of $25.19.
• These share options will vest in 48 equal monthly installments, with the first installment vesting on March 2, 2026, and have an expiration date of February 2, 2036.
• Following the option acquisition, Accardi beneficially owned 273,000 derivative securities (share options) directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting routine executive compensation that aligns management's interests with shareholders through significant equity grants, without indicating any immediate operational or financial performance changes.

Positives

• The acquisition of 68,000 Restricted Share Units (RSUs) at a $0 price indicates a significant equity grant, aligning the CEO's interests with long-term shareholder value.
• The grant of 273,000 share options, also at a $0 price, provides further incentive for the CEO to drive company performance, with an exercise price of $25.19.

Negatives

• A disposition of 2,915 ordinary shares occurred to cover tax withholding obligations, reducing direct share ownership by that amount, though this is a standard practice for equity compensation.

Future Outlook

The acquired Restricted Share Units are scheduled to vest in four equal annual installments, with the first vesting on February 2, 2027. The acquired share options will vest in 48 equal monthly installments, commencing on March 2, 2026, and will expire on February 2, 2036.

Industry Context

StockSavvy.ai notes that the granting of equity awards such as Restricted Share Units and stock options to a Chief Executive Officer is a common practice in the biotechnology and pharmaceutical industry. This compensation structure is designed to align executive incentives with long-term company performance and shareholder returns, encouraging leadership to focus on strategic growth and value creation. The vesting schedules are typical for retaining key talent over several years.

Comparison to Industry Standards

• The structure of equity grants, including RSUs and stock options with multi-year vesting schedules, is consistent with executive compensation packages observed at comparable biotech firms like Moderna (MRNA) or BioNTech (BNTX), which frequently use such incentives to retain and motivate leadership.
• The disposition of shares for tax withholding is a standard, non-discretionary event common across all industries when equity awards vest, mirroring practices seen at companies of similar market capitalization and growth stage.

Stakeholder Impact

• Shareholders: The equity grants to the CEO are intended to align his long-term interests with shareholder value creation, potentially leading to more focused strategic decisions aimed at increasing stock price.
• Employees: The grants are part of an existing incentive plan, which may signal stability in executive compensation practices and potentially broader employee incentive programs.

Next Steps

• First annual vesting of Restricted Share Units on February 2, 2027.
• Ongoing monthly vesting of share options, commencing March 2, 2026.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation transactions, including equity grants and a tax-related share disposition. While the grants align the CEO's interests with shareholders, these are standard events and do not provide new information that would fundamentally alter the investment thesis or warrant a change from a 'hold' recommendation based solely on this filing.

Keywords

Centessa Pharmaceuticals, CNTA, Form 4, Insider Transaction, Executive Compensation, Restricted Share Units, Stock Options, Equity Grant, CEO